Sox10 Controls Migration of B16F10 Melanoma Cells through Multiple Regulatory Target Genes

Ikjoo Seong, Hyun Jung Min, Jung-Hyun Lee, Chang-Yeol Yeo, Dong Min Kang, Eok-Soo Oh, Eun Sook Hwang, Jaesang Kim*

Division of Life and Pharmaceutical Sciences, Ewha Womans University, Seoul, Korea

Abstract

It is believed that the inherent differentiation program of melanocytes during embryogenesis predisposes melanoma cells to high frequency of metastasis. Sox10, a transcription factor expressed in neural crest stem cells and a subset of progeny lineages, plays a key role in the development of melanocytes. We show that B16F10 melanoma cells transfected with siRNAs specific for Sox10 display reduced migratory activity which in turn indicated that a subset of transcriptional regulatory target genes of Sox10 is likely to be involved in migration and metastasis of melanoma cells. We carried out a microarray-based gene expression profiling using a Sox10-specific siRNA to identify relevant regulatory targets and found that multiple genes including melanocortin-1 receptor (Mc1r) partake in the regulation of migration. We provide evidences that the effect of Sox10 on migration is mediated in large part by Mc1r, a transcription factor downstream to Sox10. Among the mouse melanoma cell lines examined, however, only B16F10 showed robust down-regulation of Sox10 and inhibition of cell migration indicating that further dissection of dosage effects and/or cell line-specific regulatory networks is necessary. The involvement of Mc1r in migration was studied in detail in vivo using a murine metastasis model. Specifically, B16F10 melanoma cells treated with a specific siRNA showed reduced tendency in metastasizing to and colonizing the lung after being injected in the tail vein. These data reveal a cadre of novel regulators and mediators involved in migration and metastasis of melanoma cells that represents potential targets of therapeutic intervention.

Introduction

Melanocytes originate from the neural crest cells during embryonic development [1,2]. Like other cell types from the same lineage, developing melanocytes undergo an extensive migration prior to fully differentiating into pigment producing cells of epidermis and hair follicles. Melanoma cells are malignant cancer cells of melanocytes. Highly metastatic, primary melanomas localized to epidermis are normally not life-threatening, but no efficient treatments exist post metastatic conversion [2,3]. It has been shown that the very differentiation program that dictates migration during embryogenesis predisposes melanoma cells to metastasis [2,4]. In particular, Weinberg and co-workers compared the metastatic behavior of melanocytes, fibroblasts, and epithelial cells after introducing identical set of transforming genes to each cell type and found that melanocytes attain metastatic characteristics by far the most efficiently [4]. This implies that a set of lineage specific factors expressed in melanocytes but not in others are at least partly attributable for the metastatic proclivity of this cell type.

Sox10 is a transcription factor belonging to the HMG-box transcription factor family expressed in neural crest stem cells and a subset of derivative lineages including melanocytes [5,6]. In addition to its role as a multipotency factor in stem cells, Sox10 has been implicated in expression of lineage specific genes in glia and melanocytes [7,8,9]. Homozygous loss-of-function mutation in Sox10 is embryonic lethal, but the critical role Sox10 plays in melanocyte development is evident as seen by the reduced number or absence of cells expressing specific markers [10]. Also, heterozygous loss-of-function mutations, including the frame shift mutation in *Dom* mouse, result in melanocytic phenotype with reduced extent of pigmentation in the belly and limb extremities [10,11,12]. Given the effect of differentiation program inherent to melanocytes on migration and metastasis, we sought to determine if Sox10 regulates migration and metastatic behaviors of melanoma. Several studies regarding the role of Sox10 in melanoma indicate that Sox10 is expressed in most if not all primary and metastatic melanoma cells and drives the expression of nestin which is correlated with poor prognosis [13,14,15]. Interestingly, Agnar- dotir and co-workers showed that inhibition of Sox10 expression with siRNA led to down-regulation of migration in the case of WM115 melanoma cells but not in the case of WM793 cells suggesting that the role of Sox10 is not equivalent in all melanoma cells [16]. This in turn indicates that in order to analyze the role of Sox10 in migration and isolate relevant down-stream target genes, it is necessary to select an appropriate melanoma cell line.

Citation: Seong I, Min HJ, Lee J-H, Yeo C-Y, Kang DM, et al. (2012) Sox10 Controls Migration of B16F10 Melanoma Cells through Multiple Regulatory Target Genes. PLoS ONE 7(2): e31477. doi:10.1371/journal.pone.0031477

Editor: John D. Minna, University of Texas Southwestern Medical Center at Dallas, United States of America

Received January 27, 2011; Accepted January 12, 2012; Published February 21, 2012

Copyright: © 2012 Seong et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF: 2010-0028042) and by a grant (2010K000803) from the National Research and Development Program for Cancer Control, Ministry of Health, Welfare and Family Affairs, Republic of Korea. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: jikim1964@ewha.ac.kr
Here, we used RNA interference technique to demonstrate the role of Sox10 on migration in B16F10 melanoma cells and to identify its potential transcriptional regulatory targets. We show that multiple targets of Sox10 including Mc1r, the key signaling factor in skin and hair pigmentation, are involved as effectors in B16F10 melanoma cell migration [17]. We also present data that indicate microphthalmia-associated transcript factor, Mitf, an established target of Sox10 and a critical regulator of melanocyte development, likely mediates much of the effect of Sox10 with regards to migration of B16F10 cells [18,19,20]. Finally, using a murine in vivo metastasis model we confirm the involvement of Mc1r in migration and metastasis of melanoma. Together, these data establish a novel group of genes involved in regulation of melanoma migration and metastasis some of which may represent potential novel targets of therapeutic intervention.

Results

We first sought to determine if Sox10 is involved in regulating migratory behavior of B16F10 melanoma cells. To this end, we transfected B16F10 melanoma cells with two independent siRNAs specific for murine Sox10 (the sequences of siRNAs are listed in Table S1). In 24 hours, Sox10 was undetectable in most of the cells while the expression was maintained in the cells transfected with control siRNAs (Fig. 1A–H). Importantly, cells transfected with the Sox10-specific siRNAs showed a significant reduction in migration compared to the control cells in transwell migration assays (Fig. 1I–M). This was not due to the varying replating efficiency as we observed no difference between the cell populations (data not shown). We tested two pairs of control and specific siRNAs for Sox10 to rule out the ‘off-target’ effects. The two pairs showed essentially the same effects on Sox10 expression and on cell migration. We examined if down-regulation of Sox10 induced apoptosis or senescence which could explain the observed difference between the cell populations. TUNEL assay and senescence-associated β-galactosidase assay were carried out and showed that neither of the two processes was taking place (Figs. S1 and S2).

Sox10, a transcription factor, presumably regulates the expression of other genes that function as the ‘effector’ genes of migration of melanoma cells. We thus performed a microarray screen using siRNA-treated cells in order to identify candidate Sox10-regulated genes involved in melanoma cell migration (Table 1). The complete microarray data from triplicate trials are deposited in the Gene Express Omnibus (GEO) database [GEO: GSE25501]. Table 1 shows genes down-regulated by more than 2.5 fold in all triplicates upon transfection of a Sox10-specific siRNA. Sox10 itself showed approximately three fold down-regulation as the result of specific siRNA transfection. One of the established targets of Sox10 in melanocytes, Mitf was also shown to be down-regulated by about three fold attesting to the validity of results from the screen [18,19]. We confirmed the results from the microarray screen using quantitative RTPCR for several down-regulated and unaffected genes using both pairs of control and Sox10-specific siRNAs (Fig. 2; sequences of oligonucleotide primers are listed in Table S2).

In identifying effector genes of migration that are downstream to Sox10, we focused on the subset of genes whose protein products are either localized to cellular membrane or associated with cell motility as genes of such categories are likely to be directly involved in cellular migration. To this end, 6 genes, Tn7sf1, Lims2, Tspan10, P2ry2, Hyal1, and Mc1r were selected. While some of these genes have previously been implicated in cell migration and/or metastasis, others have not been functionally characterized [21,22,23]. We generated a specific siRNA for each of these genes and tested for their efficacy in reducing the target mRNA and in inhibiting migration of B16F10 cells. Quantitative RTPCR analysis showed that all of the siRNAs were effective in down-regulating their target genes (Fig. 3A). Transwell migration assays showed that down-regulating Hyal1, Tspan10, and Mc1r resulted in clearly reduced migration of the melanoma cells (Fig. 3D, 3F, 3I). In contrast, no visible effects were seen with siRNAs for Lims2, P2ry2 and Tm7sf1 (Fig. 3E, 3G, 3H). A universal control (Fig. 3B) and WT1-Sox10 (Fig. 3C) were used as negative and positive controls respectively. We thus define multiple potential effectors of migration downstream to Sox10 in melanoma cells.

Much of the role Sox10 plays in melanocytes is supposedly mediated by one of its established direct targets, Mitf, a transcription factor belonging to the basic-helix-loop-helix leucine zipper transcription factor family [24]. As described above, Mitf is down-regulated upon siRNA-mediated down-regulation of Sox10 which was confirmed by RTPCR analysis as well (Fig. 4A). We sought to determine if Mitf is also involved in regulating migration of melanoma cells. A battery of specific siRNAs was designed and tested for efficacy in down-regulating Mitf by RTPCR (Fig. 4G) and in inhibiting migration of melanoma cells (Fig. 4B–F). Indeed, a significant reduction in migration was seen when the specific siRNAs were transfected. Apoptosis and senescence were not responsible for the apparent differences among the cell populations (Figs. S1 and S2). To test if the 6 target genes of Sox10 were regulated by Mitf, their expression levels were examined in the cells transfected with the Mitf siRNAs. Consistent with a previous report, Mc1r was regulated by Mitf [25]. Of the remaining 5 genes, Hyal1 and Tspan10 were shown to be clearly downstream to Mitf while Lims2, P2ry2, and Tm7sf1 did not appear to be so (Fig. 4G). These data thus propose a novel regulatory network initiated by Sox10 and mediated by Mitf that culminates in a group of effector genes for migration of melanoma.

We examined two other mouse melanoma cell lines, Cloudman S91 and Melan-a for the involvement of Sox10 in migration (Fig. S4). Although various transfection protocols were attempted, the efficiency of Sox10 down-regulation by specific siRNA was significantly less in these cells than in B16F10 (Fig. 2A), and consequent down-regulation of Mitf and Mc1r was also clearly less efficient. Interestingly, migration was not at all affected by down-regulation of Sox10 in both cell lines (see Discussion).

Subsequent in-depth analyses were focused on Mc1r. One well-established function of Mc1r in melanocytes and melanoma is to mediate the melanogenic signal [17]. Interestingly, several studies have reported that melanocortin stimulating hormone (MSH), a melanogenic ligand of Mc1r, inhibits migration and metastasis of melanoma cells [26,27,28]. This was confirmed using transwell migration assay in our hands as well (data not shown). In contrast, a more recent study reported that another ligand of Mc1r, agouti signal protein stimulated migratory activity of melanoma cells [29]. Collectively, these data indicate that Mc1r is somehow involved in mediating migratory signaling in melanoma. We thus generated additional Mc1r-specific siRNA molecules for transfection into B16F10 melanoma cells. Quantitative RTPCR showed that all three specific siRNAs reduced the level of Mc1r transcript (Fig. 5A), and transwell migration assay showed that each of the siRNAs led to reduction in melanoma migration (Fig. 5B–G). Once again, Apoptosis and senescence were not responsible for the apparent differences among the cell populations (Figs. S1 and S2).

We next examined the potential role of Mc1r in metastasis of melanoma using an established in vivo model. Injection of B16F10 melanoma cells into tail veins of congenic C57BL/6 mice leads to
pulmonary metastasis of these cells which can be quantitated by counting clonal colonies. Involvement of specific genes in the metastasis of B16 melanoma cells has been tested using transient transfection of siRNAs in this system [30,31]. From the siRNAs tested in vitro, we selected WT1-Mc1r which was the highly effective in down-regulating Mc1r expression and melanoma migration. As for the control, MT1-Mc1r, whose sequence contains 5 mismatches to WT1-Mc1r, was used. Treatment of B16F10 cells with these siRNAs did not differentially affect the cell growth as evidenced by cell cycle phase analysis and MTT assay (data not shown). We also examined cellular proliferation by BrdU labeling at various time points subsequent to siRNA transfection up to 18 days and showed that at all time points the two cell populations were equivalent in this regard (Fig. S3). Cells, transfected either with MT1-Mc1r or WT1-Mc1r 24 hours before injection, were injected into tail veins of multiple recipient mice, and lungs were harvested and examined visually for melanoma clones after 18 days. There was a clear and significant difference in the number of clones between the two populations of mice (Fig. 6A–C). Taken together with the data from in vitro experiments, these results support the hypothesis that Mc1r is required for efficient migration and thereby the metastasis of melanoma cells.

Discussion

The notion that key genes in development and differentiation of melanocytes are also involved in metastasis of melanoma strongly suggests that elaboration of molecular function of such genes would reveal much about the mechanism of metastasis [4]. In this
study, we show that the cascade of gene expression initiated by Sox10 and subsequently mediated in part by Mitf likely represents an important regulatory axis of migration and metastasis in a subset of melanoma cases. These two transcription factors have been established as key regulators of differentiation, proliferation, and survival of melanocytes. Such involvement in multiple aspects has in turn made it difficult to identify and analyze their role in migration of developing melanocytes. In this regard, B16F10 melanoma cells, highly migratory and impervious to down-regulation of Sox10 and Mitf for survival at least short term, have been useful. Strictly speaking, the current study does not warrant the extension of the novel role of Sox10 and Mitf to developing melanocytes. However, at least in the case of zebrafish it has been reported that mutations in Sox10 inhibit migration of melanoblasts prior to their death by apoptosis [32]. Plus, it would be an extraordinary coincidence if melanoma co-opted the two lineage specific transcription factors for functions not existent in the precursor cell type.

Figure 2. Confirmation of microarray expression profiling. (A) Quantitative real time RT-PCR assays were carried out using B16F10 cells transfected with the MT1-Sox10 or WT1-Sox10. A subset of genes that showed down-regulation by WT1-Sox10 in the microarray assay by 2.5 fold or higher in all triplicates (Table 1) and two non-target genes whose expression levels were unchanged (Ald1a and Ctbp1) were used to validate the results from the microarray assay. The effect of Sox10 knockdown by the specific siRNA on the expression level of each target gene is expressed relative to that of the control siRNA after normalization with GAPDH expression level. Values represent the average of three independent real-time PCR experiments each carried out in duplicates, and error bars represent standard deviations. (B) Real time RT-PCR carried out with MT2-Sox10 and WT2-Sox10. The asterisk (*) represents a significant difference with the p value of <0.05.

doi:10.1371/journal.pone.0031477.g002
| Accession No. | Gene name                                      | Symbol   | Fold change |
|---------------|------------------------------------------------|----------|-------------|
| BC1:58603     | ATP-binding cassette, sub-family A (ABC1), member 12 | Abca12   | −6.04       |
| NM_009308     | synaptotagmin IV                                | Syt4     | −4.74       |
| NM_175475     | cytochrome P450, family 26, subfamily b, polypeptide 1 | Cyp26b1 | −4.08       |
| AF154337      | transmembrane 7 superfamily member 1            | Tm7sf1   | −4.03       |
| NM_000868     | proteolipid protein                             | Plp      | −4.00       |
| NM_009280     | synovial sarcoma translocation, Chromosome 18   | Ssl8     | −3.73       |
| NM_144862     | LIM and senescent cell antigen like domains 2   | Lims2    | −3.58       |
| NM_145363     | oculospanin                                     | Oscp     | −3.57       |
| NM_177740     | RGM domain family, member A                     | Rgma     | −3.23       |
| NM_172584     | inositol 1,3,4-triphosphate 5/6 kinase          | Itpk1    | −3.19       |
| NM_009177     | sialytransferase 4A (beta-galactoside alpha-2,3-sialytransferase) | Siat4a | −3.15       |
| NM_008618     | malate dehydrogenase 1, NAD (soluble)          | Mdih1    | −3.14       |
| NM_008773     | purinergic receptor P2Y, G-protein coupled 2    | P2ry2    | −3.13       |
| NM_008601     | microphthalmia-associated transcription factor  | Mitf     | −3.10       |
| NM_145933     | beta galactoside alpha 2,6 sialytransferase 1   | St6gal1  | −3.05       |
| NM_144862     | LIM and senescent cell antigen like domains 2   | Lims2    | −3.04       |
| NM_008125     | gap junction membrane channel protein beta 2    | Gjb2     | −2.99       |
| NM_001014973  | sorting nexin 13                               | Snx13    | −2.99       |
| XM_001471531  | mutated in colorectal cancers                   | Mcc      | −2.93       |
| NM_001033217  | prickle like 1 (Drosophila)                     | Prickle1  | −2.92       |
| NM_001437     | SRY-box containing gene 10                      | Sox10    | −2.90       |
| NM_008899     | protein phosphatase 1, regulatory (inhibitor) subunit 14B | Ppp1r14b | −2.89       |
| NM_008963     | prostaglandin D2 synthase (brain)               | Ptgsd    | −2.85       |
| NM_008317     | hyaluronidase 1                                  | Hyal1    | −2.85       |
| NM_010777     | myelin basic protein                            | Mbp      | −2.82       |
| NM_008238     | Rab38, member of RAS oncogene family            | Rab38    | −2.81       |
| NM_001160     | protein kinase, cGMP-dependent, type 1           | Prkg1    | −2.79       |
| NM_011359     | tissue inhibitor of metalloproteinase 2          | Timp2    | −2.79       |
| NM_021883     | tropomodulin 1                                  | Tmod1    | −2.76       |
| NM_053077     | membrane associated transporter protein          | Matp     | −2.76       |
| NM_026794     | differentially expressed in B16F10 1            | Deb1     | −2.76       |
| NM_028017     | N-ethylmaleimide sensitive fusion protein attachment protein gamma | Napg | −2.73       |
| NM_173401     | F-box protein 44                                 | Fbxo44   | −2.72       |
| NM_008156     | glycosylphosphatidylinositol specific phospholipase D1 | Gpld1 | −2.71       |
| NM_010271     | glycerol-3-phosphate dehydrogenase 1 (soluble)  | Gpd1     | −2.70       |
| NM_007943     | epidermal growth factor receptor pathway substrate 15 | Eps15 | −2.68       |
| NM_011797     | carbonic anhydrase 14                            | Car14    | −2.65       |
| AF035643      | vesicle-associated membrane protein 5            | Vamp5    | −2.63       |
| NM_013807     | polo-like kinase 3 (Drosophila)                 | Pik3     | −2.62       |
| NM_008559     | melanocortin 1 receptor                         | Mc1r     | −2.60       |
| NM_007502     | ATPase, Na+/K+ transporting, beta 3 polypeptide | Atplb3   | −2.59       |
| NM_008139     | guanine nucleotide binding protein, alpha q polypeptide | Gnaq | −2.59       |
| NM_008397     | integrin alpha 6                                | Itgα6    | −2.58       |
| NM_011923     | angiopoietin-like 2                             | Angpt1   | −2.57       |
| NM_145439     | transmembrane channel-like gene family 6        | Tmc6     | −2.56       |
| NM_053110     | glycoprotein (transmembrane) mmb                 | Gpmmb    | −2.56       |
| NM_021889     | synaptotagmin 9                                 | Syt9     | −2.56       |
| NM_007905     | polyhomeotic-like 1 (Drosophila)                | Phc1     | −2.56       |
| NM_080793     | SET domain-containing protein 7                 | Set7     | −2.55       |
| NM_172992     | putative homeodomain transcription factor 2      | Phht2    | −2.54       |
It has been questioned how these two genes, especially Mitf, could be involved in such multiple aspects of melanocyte biology some of which appear to be mutually in conflict [20]. For example, how they impart positive effects on both proliferation and differentiation of melanocytes has yet to be answered although the dosage effect has been proposed as a partial explanation. Our study adds on to the complexity by implicating these two transcription factors in migration of melanocytes and melanoma. One possible approach in dissecting the situation is to find targets of Sox10 and Mitf that are involved uniquely in migration but not in survival, proliferation, or differentiation. The genes identified in this study whose expression is altered by suppression of Sox10 should comprise the pool of genes for such future analyses. Clearly, genes that are up-regulated also represent potential regulatory effectors of migration although they are not examined in this study.

It should be noted that whether the Sox10-Mitf axis is functional in regulating migratory behavior of all melanoma is questionable at this stage. First, Sox10 appears to be broadly expressed in both metastatic and non-metastatic melanomas [13,14]. Secondly, in a recent study, Agnarsdottir and co-workers showed that down-regulation of Sox10 differentially affects migration in different melanoma cell lines [16]. Consistently, our preliminary data suggest that Sox10 is not involved in promoting migration in Cloudman S91 and Melan-a cells unlike in B16F10 cells (Fig. S4). We cannot rule out that this lack of regulatory effect results from the less efficient down-regulation of Sox10 which we were able to achieve in these cells. Still, that no effect was seen at all in migration strongly suggests that an alternative explanation should be sought. Sox10-Mitf axis may be co-opted for different roles in different melanoma cells, and it may thus be possible or even necessary to group melanomas into distinct sets based on the role of Sox10-Mitf axis. Another issue to be addressed further concerns the exact nature of migration regulated by Sox10-Mitf axis. Our preliminary data indicates that both chemotactic and chemokinetic migrations are promoted in B16F10 cells by Sox10 as migration was down-regulated by siRNA treatment even when identical culture media were used in upper and lower chambers in transwell assays (Fig. S5). However, the degree of down-regulation was less than that with the use of differential media suggesting chemotactic component is also present.

It is interesting that the three of the six Sox10 target genes studied here which Mitf also appears to regulate are those that affect migration. This seems to indicate that much of the effect of Sox10 on melanoma migration is in fact mediated by Mitf although an exhaustive study needs to be carried out with more genes from the microarray screen. Hyal1, a hyaluronidase, cleaves hyaluronan which is a polysaccharide composed of repeating disaccharides of glucouronic acid and N-acetylgalactosamine [33]. Although best known as a component of extracellular matrix, short hyaluronan fragments generated from cleavage by hyaluronidase have been shown to participate in cell signaling pathways including those that regulate proliferation and migration [33,34].

Table 1.

| Accession No. | Gene name                      | Symbol | Fold change |
|---------------|--------------------------------|--------|-------------|
| NM_176996     | smooth homolog (Drosophila)    | Smo    | –2.54       |
| NM_011390     | solute carrier family 12, member 7 | Slc12a7 | –2.52       |
| NM_130886     | caspase recruitment domain family, member 14 | Card14 | –2.52       |
| NM_175445     | Ras association (RalGDS/AF-6) domain family 2 | Rassf2 | –2.50       |
| NM_010164     | eyes absent 1 homolog (Drosophila) | Eya1   | –2.50       |

Fold change is in comparison to MT1-Sox10 transfected cells. Microarray screening was carried out in triplicates. Genes that show down-regulation by 2.5 fold or higher.

In at least one report, hyaluronan fragments have been shown to induce cytokine and metalloprotease expression and promote motility of melanoma [35]. It would be interesting to test in our system if Hyal1, regulated by Sox10-Mitf axis, is in fact cleaving hyaluronan to activate a signaling pathway in promotion of cell migration. Tspan10 belongs to a family of membrane proteins known as tetraspanins [36]. Little is known about the function of Tspan10 although the existence of orthologues throughout vertebrates strongly suggests that it has a conserved and important function. The family members are variously implicated in regulation of cell signaling, adhesion, motility, fusion, and viral infection [36]. Thus, it would not be surprising if Tspan10 partakes in regulating migration of melanoma as shown in our study although detailed mechanisms need further analyses.

We propose Mc1r as an important mediator gene of migratory signaling in this study. Aside from the in vitro assays for its effect on migration, we also performed in vivo assay and showed that Mc1r can potentially regulate metastatic behavior of melanoma cells. It should be noted that although a popular model, the experimental system based on intravenous delivery of cells represents examination of extravasation rather than overall metastasis [30,31]. A more rigorous model will be needed to confirm that Mc1r can affect exit from the primary tumor, the first step of metastasis.

Interestingly, it appears that Mc1r can bind multiple ligands and can impart at least two distinct signals, one melanogenic and another pro-migratory. First, agouti signal protein, a well-established ligand of Mc1r has been shown to stimulate migration of melanoma cells to a significant level [29]. Second, α-MSH, another well-established ligand of Mc1r inhibits migration and metastasis of melanoma cells [26,27,28]. Also, a member of the β-defensin family, previously studied mostly for its role in immunity, has been recently reported to be a specific ligand of Mc1r, [37]. Consistently, it has been reported that Mc1r is coupled to more than one signaling pathways and that Mc1r shows an agonist-independent constitutive activity [17,38]. It is then possible that constitutive signaling initiated by Mc1r in the absence of melanogenic ligand is promigratory rather than melanogenic although it is very difficult if not impossible to show that our in vitro system is entirely devoid of any known or unknown Mc1r ligands. It goes without saying that it would be important down the road to dissect the pro-migratory signaling pathway of Mc1r apart from the melanogenic signaling pathway. Components of pro-migratory pathway represent potential targets for inhibition of metastasis which apparently is the key to surviving the scourge of melanoma.

Materials and Methods

Cell culture

Mouse melanoma cell line B16F10 cells were obtained from ATCC and cultured in DMEM (WelGENE Inc.) supplemented...
with 10% fetal bovine serum (FBS; Hyclone), 1% penicillin and 1% streptomycin in a humidified chamber with 5% CO2 at 37°C. HT1080 cells were grown in MEM (Invitrogen) supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate and 1% penicillin and 1% streptomycin in a humidified chamber with 5% CO2 at 37°C.

Immunostaining

Cells were fixed in 4% paraformaldehyde in PBS. Immunocytochemistry with the monoclonal anti-Sox10 antibody has been described [39]. For DAPI staining, cells were incubated with DAPI (Sigma) at 0.1 μg/ml in PBS at RT for 10 min. Cells were viewed and photographed using Axiovert 200 epifluorescence microscope (Carl Zeiss Inc.) equipped with a digital imaging system.

siRNA experiments

Synthetic 21-nucleotide RNA duplexes were purchased from Dharmaco Research Inc. Target sequences for specific genes were selected using siDESIGN® Center tool (http://www.dharmacon.com/designcenter/designcenterpage.aspx). As a universal control, siCONTROL Non-Targeting siRNA #2 was used. Other control mutant (MT) siRNAs were designed to contain 5 nucleotide mismatches to corresponding wild type (WT) siRNAs. Cells were trypsinized and replated 1 day prior to transfection at the density of 5 × 10^5 cells per 60 mm dish. The siRNAs with the final concentration of 200 nM were transfected into B16F10 cells using Oligofectamine (Invitrogen) according to the manufacturer’s instruction. siRNAs were typically applied for 24 hours.

Gene expression profiling

Total RNA was prepared using an RNasy Mini Kit (QIAGEN) according to the manufacturer’s instructions and subsequently processed to yield biotinylated cRNA using the Ambion Illumina RNA amplification kit (Ambion, Austin, USA) according to the manufacturer’s instructions. The labeled cRNA preparations were applied to Mouse-6 Expression BeadChip (Illumina, Inc). Detection of array signal was carried out using Amersham fluorescin-streptavidin-Cy3 (GE Healthcare Bio-Sciences, Little Chalfont, UK) following the bead array manual. Arrays were scanned with an Illumina Bead Array Reader confocal scanner according to the manufacturer’s instructions. Raw data were extracted using the software provided by the manufacturer, Illumina BeadStudio (Gene Expression Module). Array data were filtered by detection value = 0.66 (similar to signal to noise) in at least 80% samples (we applied a filtering criterion for data analysis; higher signal value was required to obtain a detection p-value, 0.05). Selected gene signal value was transformed by logarithm and normalized by quantile method. The comparative analyses between test samples and control samples were carried out using fold-change. The complete microarray data from triplicate trials were deposited in the Gene Express Omnibus (GEO) database [GEO: GSE25501]. All data are MIAME compliant. Go-ontology analysis for significant probe list was performed using PANTHER (http://www.pantherdb.org).

Real time RTPCR

Total RNA was extracted using an RNasy Mini Kit (QIAGEN) according to the manufacturer’s instructions. cDNA synthesis was carried out with SuperScript® First-Strand Synthesis System for RT-PCR (Invitrogen) using oligo-dT primers following the manufacturer’s instructions. Quantitative analyses of gene expression level were performed by real-time PCR with SYBR Green Master mix (Applied Biosystems). PCR was carried out on

---

**Figure 3. Targets of Sox10 regulate migration of B16F10 melanoma cells.** (A) Quantitative RTPCR assay was carried out to test the efficacy of siRNAs directed for the selected genes. For each gene, the knockdown effect of the specific siRNA is expressed relative to that of a universal control siRNA (siCONTROL Non-Targeting siRNA #2) after normalization with GAPDH expression level. Values represent the average of three independent real-time PCR experiments each carried out in duplicates, and error bars represent standard deviations. The asterisk (*) represents a significant difference with the p value of <0.05. (B-I) B16F10 cells were treated with the universal control siRNA, WT1-Sox10 or a specific siRNA for each of the selected Sox10 target genes and subjected to transwell migration assay: Control (B), Sox10 (C), Hyal 1 (D), Lim32 (E), Mc1r (F), P2ry2 (G), Tm7sf1 (H), and Tspan10 (I). Representative results are presented. doi:10.1371/journal.pone.0031477.g003
an ABI Prism 7300 Sequence Detection System using a two-step thermal cycling protocol of 40 cycles of 95°C for 15 s and 60°C for 1 min, preceded by an initial 95°C for 10 min for activation of AmpliTaq Gold® DNA polymerase. The expression value of tested genes was calculated using the delta Ct method with normalizing to the GAPDH expression level. Primer pairs used for PCR are listed in Table S2.

Transwell migration assay
Transwell migration assays were performed using transwell chambers (8 μm polycarbonate membrane, Corning). Lower-chamber side filter was coated for 1 hour with 0.1% gelatin B. After 24 hours of siRNA treatment, B16F10 cells were harvested in DMEM containing 2% FBS. Typically, $1 \times 10^5$ cells were seeded in the upper chamber which was placed over the lower chamber.
containing HT1080-conditioned media. Migration was allowed to proceed for 6 hours at 37°C, and cells were fixed with 70% Methanol and stained with 0.5% EosinB-Hematoxylin solution. Cells remaining on the upper-chamber side of the filter were removed with cotton swabs. The number of migrated cells was determined by counting stained cells from multiple randomly selected microscopic visual fields.

In vivo metastasis assay
B16F10 cells, treated with WT1-Mc1r or MT1-Mc1r siRNA for 24 hours were washed twice with PBS and detached with trypsin. After serum inactivation, cells were again washed and resuspended in PBS. Male C57BL/6 mice, 8 weeks old, were injected in the tail vein with 2x10^6 cells in 400 µl. After 18 days, mice were euthanized by standard carbon dioxide asphyxiation. The lungs were removed and rinsed, and the pulmonary metastatic colonies of B16F10 cells were counted by visual inspection. All animal studies were conducted in accordance with the IACUC guidelines and were approved by the IACUC committee at Ewha Womans University (approval ID: ELAGC-09-1019 and IACUC 2010-15-2).

More information is available in Methods S1.

Supporting Information
Figure S1  TUNEL assay. B16F10 cells were transfected with indicated siRNAs for 24 hours and replated as in the transwell migration assay. TUNEL assay was performed using TUNEL-Enzyme and TUNEL-Label (Roche). DNase I treated cells were used as positive controls for TUNEL staining. Cells were also stained with specific antibodies to confirm down-regulation of Sox10 (A) and MITF (B). For Mc1r (C), RTPCR was performed in duplicates to confirm the down-regulation (see also Fig. 4G and Fig. 5A). Ald1a and Ctbp1 are negative controls for siRNA treatment for Mc1r.

(PDF)

Figure S2  Cell staining for senescence-associated beta-galactosidase activity. B16F10 cells were transfected with indicated siRNAs for 24 hours and replated as in the transwell migration assay. For the positive control, B16F10 cells treated with 50 µM doxorubicin for 3 days were used. Typical X-gal staining and morphological change during senescence are seen only in doxorubicin treated cells.

(PDF)
Cloudman S91 cells transfected with the MT1 or WT1 Sox10 siRNA. Values represent the average of three independent real-time PCR experiments each carried out in duplicates, and error bars represent standard deviations. The asterisk (*) represents a significant difference with the p value of <0.05. Cloudman S91 cells were treated with the MT1 (B) or WT1 (C) Sox10 siRNA and subjected to transwell migration assay. (D) The Graph represents quantitation of transwell migration assay. The effect of Sox10 knockdown on the number of cells that migrated through the filter pores is shown in percentile relative to the control case. Values represent the average of 4 independent trials, and error bars represent standard deviations. (E) Quantitative real time RTPCR assays were carried out using Melan-a cells transfected with the MT1 or WT1 Sox10 siRNA. Values represent the average of three independent real-time PCR experiments each carried out in duplicates, and error bars represent standard deviations. The asterisk (*) represents a significant difference with the p value of <0.05. Melan-a cells were treated with the MT1 (F) or WT1 (G) Sox10 siRNA and subjected to transwell migration assay. (H) The Graph represents quantitation of transwell migration assay. The effect of Sox10 knockdown on the number of cells that migrated through the filter pores is shown in percentile relative to the control case. Values represent the average of 4 independent trials, and error bars represent standard deviations.

Methods S1 Supplementary materials and methods. More information on the TUNEL Assay, Senescence-associated beta-galactosidase activity assay, and BrdU labeling. (PDF)

Table S1 List and target sequence of siRNAs used for RNA interference assay. (DOC)

Table S2 List and sequence of oligonucleotide primers used for real time RTPCR. (DOC)

Acknowledgments
We thank WJ Lee and SW Kang for helpful discussions.

Author Contributions
Conceived and designed the experiments: EO ESH JK. Performed the experiments: IS HJM JL CY. Analyzed the data: IS DMK ESH JK. Wrote the paper: IS JK.

References
1. Uong A, Zon LI (2009) Melanocytes in development and cancer. J Cell Physiol 222: 38–41.
2. White RM, Zon LI (2006) Melanocytes in development, regeneration, and cancer. Cell Stem Cell 3: 242–252.
3. Jilaveanu LB, Aziz SA, Khuger HM (2009) Chemotherapy and biologic therapies for melanoma: do they work? Clin Dermatol 27: 614–625.
4. Gupta PB, Kuperwasser C, Brunet JP, Ramaswamy S, Kuo WL, et al. (2005) The melanocyte differentiation program predisposes to metastasis after neoplastic transformation. Nat Genet 37: 1047–1054.
5. Kelsh RN (2006) Sorting out Sox10 functions in neural crest development. Bioessays 28: 788–798.
6. Kim J, Lo I, Dordam E, Anderson DJ (2003) SOX10 maintains multipotency and inhibits neuronal differentiation of neural crest stem cells. Neuro 38: 17–31.
7. Lee KE, Nam S, Cho EA, Seong I, Limh JK, et al. (2008) Identification of direct regulatory targets of the transcription factor Sox10 based on function and conservation. BMC Genomics 9: 408.
8. Roh J, Cho EA, Seong I, Limh JK, Lee S, et al. (2006) Down-regulation of Sox10 with specific small interfering RNA promotes transdifferentiation of Schwannoma cells into myofibroblasts. Differentiation 74: 542–551.
9. Wegner M (2005) Secrets to a healthy Sox life: lessons for melanocytes. Pigment Cell Res 18: 74–83.
25. Aoki H, Moro O (2002) Involvement of microphthalmia-associated transcription factors in the development of neural crest-derived melanocytes and glia. 

24. Tachibana M (2000) MITF: a stream flowing for pigment cells. Pigment Cell Res 13: 230–240.

23. Zhang Y, Chen K, Guo L, Wu C (2010) Nestin and SOX9 and SOX10 expression factors are coexpressed in melanoma. Exp Dermatol 19: e89–94.

22. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, et al. (2009) SOX9 and SOX10 expression in superficial spreading and nodular malignant melanomas. Melanoma Res 20: 686–678.

21. Bondurand N, Pingault V, Goerich DE, Lemort N, Sock E, et al. (2000) The transcription factor Sox10 links Waardenburg-Shah syndrome (WS4)-associated hypopigmentation and deafness to WS2. J Biol Chem 275: 39378–39383.

20. Mitra D, Fisher DE (2009) Transcriptional regulation in melanoma. Hematol Oncol Clin North Am 23: 17–24.

19. Tachibana M (2000) MITF: a stream flowing for pigment cells. Pigment Cell Res 13: 230–240.

18. Garcia-Borron JC, Sanchez-Laorden BL, Jimenez-Cervantes C (2005) Melanocortin-1 receptor structure and functional regulation. Pigment Cell Res 18: 393–410.

17. Le Pape I, Paseron T, Giubellino A, Valencia JC, Wolber R, et al. (2009) Microarray analysis sheds light on the dedifferentiating role of agouti signal protein in mouse melanocytes via the Mc1r. Proc Natl Acad Sci U S A 106: 1802–1807.

16. Agnarsdottir M, Sooman L, Bolander A, Stromberg S, Rexhepaj E, et al. (2010) Spontaneous metastasis of prostate cancer is promoted by excess hyaluronan (WS4)-associated hypopigmentation and deafness to WS2. J Biol Chem 275: 39378–39383.

15. Piras F, Perra MT, Murtas D, Minerba L, Floris C, et al. (2010) The stem cell marker nestin predicts poor prognosis in human melanoma. Oncol Rep 23: 17–24.

14. Bakos RM, Maier T, Besch R, Mestel DS, Ruzicka T, et al. (2010) Nestin and SOX10 but not BRN2 are required for nestin expression in human melanoma cells. J Invest Dermatol 129: 945–953.

13. Bakos RM, Maier T, Besch R, Mestel DS, Ruzicka T, et al. (2010) SOX10 expression in superficial spreading and nodular malignant melanomas. Melanoma Res 20: 468–478.

12. Mollaaghababa R, Pavan WJ (2003) The importance of having your SOX on: role of Sox10 in the development of neural crest-derived melanocytes and glia. Oncogene 22: 3024–3034.

11. Lane PW, Liu HM (1984) Association of megacolon with a new dominant spotting gene (Dom) in the mouse. J Hered 75: 435–439.

10. Britsch S, Georich DE, Rietzhammer D, Peirano RI, Rossner M, et al. (2001) Interaction among SOX10, PAX3 and MITF, three genes altered in Waardenburg syndrome. Hum Mol Genet 9: 1907–1917.

9. Sugahara KN, Hirata T, Hayasaka H, Stern R, Murai T, et al. (2006) Tumor cells enhance their own CDH4 cleavage and motility by generating hyaluronan fragments. J Biol Chem 281: 5861–5868.

8. Toole BP (2004) Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 4: 528–539.

7. Candille SI, Kaelin CB, Cattanach BM, Yu B, Thompson DA, et al. (2007) A - defensin mutation causes black coat color in domestic dogs. Science 318: 1418–1423.

6. Hemler ME (2008) Targeting of tetraspanin proteins–potential benefits and strategies. Nat Rev Drug Discov 7: 747–758.

5. Le Pape I, Paseron T, Giubellino A, Valencia JC, Wolber R, et al. (2009) Microarray analysis sheds light on the dedifferentiating role of agouti signal protein in mouse melanocytes via the Mc1r. Proc Natl Acad Sci U S A 106: 1802–1807.

4. Amarguion M, Peng Q, Wiiger MT, Vasovic V, Bahaie E, et al. (2006) Ex vivo and in vivo delivery of anti-tissue factor short interfering RNA inhibits mouse pulmonary metastasis of B16 melanoma cells. Clin Cancer Res 12: 4055–4061.

3. Kurisu S, Sartsuga S, Yamazaki D, Yamaguchi H, Takanawa T (2005) Rac-WAVE2 signaling is involved in the invasive and metastatic phenotypes of human melanoma cells. Oncogene 24: 1309–1319.

2. Dutton KA, Pauliny A, Lopes SS, Elwood S, Carney TJ, et al. (2001) Zebrafish colourless encodes sox10 and specifies non-ectomesenchymal neural crest fates. Development 128: 4113–4125.

1. Sanchez-Mas J, Hahmann C, Gerritsen I, Garcia-Borron JC, Jimenez-Cervantes C (2005) Agouti signal protein suppresses the growth and metastasis of melanoma: involvement of alpha-melanocyte-stimulating hormone-mediated inhibition of the nuclear factor kappaB/cyclooxygenase-2 pathway. Mol Pharmacol 69: 440–451.

0. Kameyama K, Vieira WD, Tsukamoto K, Law LW, Hearing VJ (1990) Characterization and the tumorigenic and metastatic phenotype of murine melanoma cells. Int J Cancer 45: 1151–1158.